首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1542906

全球排卵症診斷市場 - 2024-2031

Global Ovulation Disorder Diagnosis Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

排卵障礙診斷市場規模

2023年，全球排卵症診斷市場規模達5.226億美元，預計2031年將達到7.6899億美元，2024-2031年預測期間複合年成長率為5.0%。

排卵障礙是女性或女孩不孕的主要原因。排卵障礙是女性月經週期中卵子生成的紊亂。這些疾病通常是由於下視丘功能障礙、卵巢早衰和多囊性卵巢症候群引起的。

排卵障礙診斷市場動態

排卵障礙診斷市場的成長是由於計劃懷孕的增加、生育率的下降以及公眾對不同排卵障礙的認知的提高而推動的

2型糖尿病患者多囊性卵巢症候群（PCOS）的盛行率預計將推動市場成長

多囊性卵巢症候群 (PCOS) 是一種常見的代謝和內分泌生殖疾病，與心血管、代謝和心理因素相關，影響全球約 7% 的女性。根據 2022 年 8 月發表在《內分泌學前沿》上的文章，糖尿病 (DM) 是全球公共衛生問題。到 2021 年，全球約有 5.37 億成年人（20-79 歲）患有糖尿病，其中大多數是較年輕的年齡層。現在，越來越多的患者在年輕時患有第 2 型糖尿病 (T2DM)，而患有 T2DM 的女性在生育期更容易受到影響。女性 T2DM 患者的生殖功能障礙正在謹慎增加。與非T2DM患者相比，T2DM患者表現出更多的臨床變化，如月經失調、多囊性卵巢等。這可能與黃體生成素和胰島素協同作用引起的細胞雄性激素水平升高有關。

此外，PCOS是由2型糖尿病和高胰島素中的內源性胰島素抗性刺激卵巢顆粒細胞引起的，這會促進小卵泡的生長和數量。 PCOS 和 T2DM 具有生化、臨床和代謝特徵。 PCOS 或 T2DM 患者之間也存在很高的重疊率。 PCOS 涉及的 T2DM 可能會導致生殖系統的評估性損傷。越來越多的 PCOS 患者推動著市場。

公眾意識的缺乏將阻礙市場的成長

然而，衛生專業人員和患者之間的先進知識差距導致了診斷延遲和護理變化。此外，缺乏針對受影響婦女的基於證據的、可獲取的資訊導致了不滿。許多女性不知道排卵，這會影響診斷資訊並導致不孕，並與各種健康風險相關。

COVID-19 影響分析

COVID-19的出現極大地影響了全球排卵症診斷市場。根據2020年7月發表在BMC Medicine上的文章，在育齡女性中，多囊性卵巢症候群（PCOS）是最常見的內分泌疾病，盛行率可能達到甚至超過10-15%。感染 COVID-19 的機會就越大。另一方面，由於交通限制和封鎖，許多患者在大流行期間難以接受常規治療。疫情期間，許多行業都處於停工狀態，這對市場產生了負面影響。

不過，由於情況要到2022年中期而不是2021年才能扭轉，病人現在可以在醫院接受治療。市場在預測期內也將呈現良好的成長。

排卵障礙診斷市場細分分析

預計多囊性卵巢症候群細分市場在預測期內（2024-2031）將以最快的複合年成長率成長

多囊性卵巢症候群預計將在預測期內提振市場。在某些情況下，女性無法產生足夠的排卵所需的荷爾蒙。當不排卵時，卵巢會形成許多小囊腫。這些囊腫會產生稱為雄性激素的荷爾蒙。患有多囊性卵巢綜合症的女性通常雄激素水平較高。這會導致女性月經週期出現更多問題，並可能導致多囊性卵巢症候群的許多症狀。如果有人月經不調，且血液檢查顯示雄性激素水平較高，則這些女性患有多囊性卵巢症候群。據克利夫蘭診所稱，PCOS 非常常見。高達 15% 的育齡婦女患有此病。未診斷和治療多囊性卵巢症候群的女性可能面臨增加心血管疾病風險的風險，包括肥胖、高血壓、懷孕糖尿病和高膽固醇。因此，診斷 PCOS 非常重要，PCOS 病例的增加導致診斷市場的需求不斷增加。目前還沒有專門診斷多囊性卵巢症候群 (PCOS) 的單一檢查。醫療保健專業人員建議進行骨盆檢查、血液檢查和超音波檢查。

排卵障礙診斷市場地域佔有率

北美地區佔全球排卵症診斷市場最大佔有率

北美在排卵障礙診斷市場中佔據主導地位，預計在預測期內將呈現類似的趨勢。由於先進的醫療基礎設施和公眾對排卵障礙診斷的認知不斷提高，預計在預測期內（2024-2031年）將保持巨大的市場規模。據美國疾病管制與預防中心稱，PCOS 是導致女性不孕症的最常見原因之一，影響 6% 至 12%（多達 500 萬）的美國育齡女性。多囊性卵巢症候群病例和女性健康意識的提高推動了北美地區的市場。此外，主要參與者正在採取合併和推出新產品等市場策略。例如，2021 年 12 月，Labcorp 收購了 Toxikon Corporation，這是一個提供一流非臨床測試服務的合約研究組織。將 Toxikon 添加到 Labcorp 藥物開發中將增強 Labcorp 強大的非臨床開發產品組合。

排卵障礙診斷市場公司及競爭格局

排卵障礙診斷市場是本地和全球公司的適度競爭的市場。為市場成長做出貢獻的一些主要參與者包括西門子醫療、通用電氣醫療、富士膠片控股、瑞士精密診斷公司、東芝醫療系統公司、銳珂醫療、熱那亞診斷、Quest Diagnostics、LabCorp 和 Esaote 等。主要參與者正在採取多種成長策略，例如治療類型的推出、收購和合作，這有助於全球排卵障礙診斷市場的成長。

例如，

2022 年 7 月，佳能醫療系統美國公司收購了總部位於明尼蘇達州明尼阿波利斯的醫療影像設備經銷商和服務供應商 NXC Imaging。

東芝醫療系統公司 (TMSC)

概述：

TMSC 是一家製造、銷售和提供醫療設備技術服務的公司，包括診斷 X 光系統、醫用 X 光 CT 系統、磁振造影系統 (MRI)、電腦斷層掃描 (CT) 診斷超音波系統、放射治療系統等。

治療類型組合：

電腦斷層掃描：該系統在傳統形態學的基礎上，提供了功能診斷、動態觀察等新的臨床價值。還能夠在 0.35 秒內旋轉一圈提供 160 毫米寬的 3D 成像覆蓋，並且掃描時間和曝光劑量更少，是患者友好的醫療護理。

全球排卵障礙診斷市場報告將提供約 65 個以上的市場資料表、65 個以上的數字以及 200 多個（大約）頁數。

Polycystic ovary syndrome (PCOS) is a common metabolic and endocrine reproductive disease associated with cardiovascular, metabolic, and psychological factors affecting around 7% of women globally. As per the article published in Frontiers in Endocrinology in August 2022, Diabetes mellitus (DM) is a global public health concern. Around 537 million adults (20-79 years old) worldwide have developed DM in 2021, mostly in the younger age group. Now, more patients are developing type 2 DM (T2DM) at a younger age, and women with T2DM are affected more often during the reproductive period. Reproductive dysfunction in women patients with T2DM is cautiously increasing. Compared with patients without T2DM, patients with T2DM show more clinical changes, such as menstrual disorders and polycystic ovaries. This may be associated with the rise in cellular androgen levels induced by the cooperation of luteinizing hormone and insulin.

In addition, PCOS results from ovarian granulosa cells' stimulation by endogenous insulin resistance in type 2 diabetes and hyperinsulinem, which promote the growth and number of small follicles. PCOS and T2DM have biochemical, clinical, and metabolic characteristics. There is also a high overlap rate between patients with PCOS or T2DM. T2DM involved by PCOS may result in evaluative injuries to the reproductive system. The more patients with PCOS drive the market.

The lack of awareness in public will hamper the growth of the market

However, advanced knowledge gaps among health professionals and patients contribute to diagnostic delays and variation in care. In addition, a dearth of evidence-based, accessible information for affected women leads to dissatisfaction. Many women are unaware of ovulation, which disorders diagnosis information and causes infertility and is linked with various health risks.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global ovulation disorder diagnosis market. As per the article published in BMC Medicine in July 2020, in women of reproductive age, polycystic ovary syndrome (PCOS) constitutes the most frequent endocrine disorder, with a prevalence that may reach or even exceed 10-15%. The more chances are there of getting infected from COVID-19. On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. Many industries are locked down in the pandemic, which negatively impacts the market.

However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Ovulation Disorder Diagnosis Market Segment Analysis

The polycystic ovarian syndrome segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)

The polycystic ovarian syndrome segment is expected to boost the market over the period of the forecast. In some cases, a female doesn't make enough of the hormones required to ovulate. When ovulation doesn't happen, the ovaries develop many small cysts. These cysts generate hormones called androgens. Females with PCOS often have high levels of androgens. This results in more problems with a woman's menstrual cycle and can cause many symptoms of PCOS. If anyone has irregular periods and higher levels of androgen shown in blood tests, these women have PCOS. According to the Cleveland Clinic, PCOS is very common; up to 15% of women of reproductive age have it. Women not diagnosed and treated for PCOS may be at risk for developing conditions that raise the risk of cardiovascular disease, including obesity, high blood pressure, gestational diabetes, and high cholesterol. Therefore, diagnosing PCOS is important and increasing cases of PCOS lead to increasing demand for the diagnosis market. There's no single test specifically diagnosing polycystic ovary syndrome (PCOS). The healthcare professionals suggested a pelvic exam, blood tests, and ultrasound.

Ovulation Disorder Diagnosis Market Geographical Share

North America region holds the largest market share of the global ovulation disorder diagnosis market

North America dominates the market for ovulation disorder diagnostics and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2024-2031) owing to advanced healthcare infrastructure and rising awareness in public regarding ovulation disorder diagnosis. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of US women of reproductive age. The cases of PCOS and increasing health awareness in women drive the market in the North American region. In addition, the key players are adopting market strategies such as mergers and new launches of the product. For instance, in December 2021, Labcorp acquired the Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. Adding Toxikon to Labcorp Drug Development bolsters Labcorp's strong nonclinical development portfolio.

Ovulation Disorder Diagnosis Market Companies and Competitive Landscape

The ovulation disorder diagnosis market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens Healthcare, GE Healthcare, Fujifilm Holdings, Swiss Precision Diagnostics, Toshiba Medical Systems Corporation, Carestream Health, Genova Diagnostics, Quest Diagnostics, LabCorp, and Esaote, among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the ovulation disorder diagnosis market globally.

For instance,

In July 2022, Canon Medical Systems USA Inc. acquired NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota.

Toshiba Medical Systems Corporation (TMSC)

Overview:

TMSC is a company which is manufactured, sells, and provisions technical services for medical equipment, including diagnostic x-ray systems, medical x-ray CT systems, magnetic resonance imaging systems (MRI), computed tomography (CT) diagnostic ultrasound systems, radiation therapy systems, and others.

Treatment type Portfolio:

Computed Tomography: The system provides new clinical values such as functional diagnosis and dynamic observation apart from conventional morphological. Also able to provide 160 mm-wide coverage of 3D imaging in one rotation with 0.35 seconds, and it is patient-friendly medical care and requires less scanning time and exposure dose.

The global ovulation disorder diagnosis market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

1. Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet By Ovulation Disorders
3.2. Market Snippet By Diagnosis
3.3. Market Snippet By End-users
3.4. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising obesity rates
  - 4.1.1.2. The increasing prevalence of diabetes
- 4.1.2. Restraints:
  - 4.1.2.1. Lack of awareness of diagnosis
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
5.5. Unmet Needs

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Ovulation Disorders

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 7.1.2. Market Attractiveness Index, By Ovulation Disorders
7.2. Polycystic Ovarian Syndrome*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Hyperprolactinemia
7.4. Luteal Phase Defect
7.5. Hypothalamus Dysfunction
7.6. Tumors
7.7. Autoimmune Oophoritis
7.8. Primary Ovarian Failure
7.9. Resistant Ovary Syndrome
7.10. Others

8. By Diagnosis

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 8.1.2. Market Attractiveness Index, By Diagnosis
8.2. Laboratory Testing of Hormones*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. CT Scan and MRI Scan of The Pituitary Gland and Hypothalamus
8.4. Ovarian Biopsy
8.5. Others

9. By End-users

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 9.1.2. Market Attractiveness Index, By End-users
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Gynecological Clinics
9.4. Diagnostic Centers
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 10.4.6.
- 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

11. Competitive Landscape

11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Treatment type Benchmarking

12. Company Profiles

12.1. Siemens Healthcare*
- 12.1.1. Company Overview
- 12.1.2. Treatment type Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. GE Healthcare
12.3. Fujifilm Holdings
12.4. Swiss Precision Diagnostics
12.5. Toshiba Medical Systems Corporation
12.6. Carestream Health
12.7. Genova Diagnostics
12.8. Quest Diagnostics
12.9. LabCorp
12.10. Esaote(*LIST NOT EXHAUSTIVE)